Ursodeoxycholic acid - RetrophinAlternative Names: liquid formulation ursodeoxycholic acid; ursodeoxycholic acid liquid
Latest Information Update: 23 Jun 2016
At a glance
- Originator Asklepion Pharmaceuticals
- Developer Retrophin
- Class Cholic acids; Gallstone therapies; Hepatoprotectants
- Mechanism of Action Apoptosis inhibitors; Cholesterol inhibitors; Immunomodulators; Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Primary biliary cirrhosis